Premium
Identification of sulfonyl‐loxoprofen as novel phase 2 conjugate in rat
Author(s) -
Shrestha Riya,
Paudel Sanjita,
Cho Piljoung,
Shrestha Aarajana,
Jeong Tae Cheon,
Lee EungSeok,
Lee Taeho,
Lee Sangkyu
Publication year - 2019
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2196
Subject(s) - chemistry , metabolite , prodrug , urine , taurine , conjugate , pharmacology , active metabolite , potency , sulfation , chromatography , biochemistry , in vitro , amino acid , biology , mathematical analysis , mathematics
Loxoprofen is a prodrug that exerts strong analgesic and anti‐inflammatory effects through its active trans‐alcohol metabolite, which is produced in the liver by carbonyl reductase. Previous metabolic studies have evaluated loxoprofen, but its sulfate and taurine conjugates have not yet been studied. We characterized the metabolomic profile of loxoprofen in rat plasma, urine, and feces using high‐resolution mass spectrometry. We identified 17 metabolites of loxoprofen in the three different biological matrices, 13 of which were detected in plasma and feces and 16 in urine. Amongst these metabolites, two novel taurine conjugates ( M12 and M13) and two novel acyl glucuronides (M14, M15) were identified for the first time in rats. In addition, we detected three novel sulfate conjugates ( M9, M10, and M11) of loxoprofen. Further study of these metabolites of loxoprofen is essential in order to assess their potency and toxicity.